$1.36
-0.02 (-1.45%)
Performance
1D
—
1W
—
1M
—
3M
—
6M
-23.16%
1Y
-67.15%
YTD
-67.15%
Open$1.40
Previous Close$1.38
Day High$1.40
Day Low$1.35
52W High$5.93
52W Low$1.07
Volume—
Avg Volume773.1K
Market Cap82.95M
P/E Ratio—
EPS$-0.38
SectorBiotechnology
Technical Indicators
Full analysis →
SMA 50
$1.68
Below
RSI (14)
47.8
Neutral
Analyst Ratings
Strong Buy
12 analysts
Price Target
+3,075.0% upside
Current
$1.36
$1.36
Target
$43.18
$43.18
$31.72
$43.18 avg
$59.84
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 34.78M | 32.14M | 39.05M |
| Net Income | 5.77M | 7.01M | 8.10M |
| Profit Margin | 16.6% | 21.8% | 20.7% |
| EBITDA | 11.08M | 11.55M | 13.91M |
| Free Cash Flow | 4.11M | 3.56M | 7.02M |
| Rev Growth | +3.0% | +6.5% | +17.8% |
| Debt/Equity | 0.16 | 0.15 | 0.16 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $265.21 | +0.28% | 74.0 | 466.74B |
| AMGN | Amgen Inc | $410.24 | +4.34% | 23.7 | 207.25B |
| GILD | Gilead Sciences Inc | $152.67 | +1.40% | — | 187.10B |
| VRTX | Vertex Pharmaceuticals Inc | $514.99 | +0.84% | 29.7 | 130.64B |
| REGN | Regeneron Pharmaceuticals | $803.90 | +0.72% | 18.6 | 80.58B |
| ALNY | Alnylam Pharmaceuticals Inc | $251.65 | +3.00% | 40.0 | 32.33B |